You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Autologous hematopoietic cell transplantation for autoimmune diseases

ID: ES SCT-10 mai 2019
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
H. Atkins,, J. Brown,, C. Bredeson,, T. Kouroukis, and the Specialized Services Oversight and Stem Cell Transplant Advisory Committee

Guideline Objective

  • To provide direction as to appropriate non-hematologic autoimmune indications for aHCT, focusing on three selected autoimmune diseases (MS, SSc, IBD),
  • To potentially identify specialized resources, in addition to (or instead of) what is provided in the cancer system, to enable safe and effective aHCT for the three selected autoimmune diseases,
  • To provide evidence to support programmatic decision making regarding indications for the three selected autoimmune disease.

Patient Population

All adult patients with MS, SSc, or IBD receiving aHCT were included.

Intended Guideline Users

The SSO and SCT Advisory Committee to inform planning of services for HCT delivery in Ontario.

Research Questions

  1. In patients with MS, is aHCT more effective than alternative therapies in halting disease progression?
  2. In patients with SSc, is aHCT more effective than alternative therapies in halting disease progression?
  3. In patients with IBD, is aHCT more effective than alternative therapies in halting disease progression?
pdf download Full Report (PDF) (761.2 Ko)